<< Back to News

New FDA Approval for KEYTRUDA®

On November 9, 2018 Merck announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Click Here to read the entire press release

Click Here to read the Prescribing Information

Click Here to read the Keytruda Medication Guide